Table 2.
Presenting complaints, co-morbidity and therapeutic characteristics of participants
| Various presenting complaints | ||
|---|---|---|
| Number of patients | % | |
| Presenting complaints | ||
| Flank Pain | 25 | 30.5 |
| Bipedal Swelling | 15 | 18.3 |
| Headache | 8 | 9.8 |
| Abdominal Pain | 7 | 8.5 |
| Abdominal Distension | 6 | 7.3 |
| Easy Fatigability | 5 | 6.1 |
| Dizziness | 4 | 4.9 |
| Breathlessness | 2 | 2.4 |
| Early Morning Facial Puffiness | 2 | 2.4 |
| General Body Weakness | 2 | 2.4 |
| Vomiting | 2 | 2.4 |
| Hematuria | 2 | 2.4 |
| Palpitation | 1 | 1.2 |
| Polyuria | 1 | 1.2 |
| Co-morbid at the time of presentation | ||
| No co-morbidity | 33 | 40.2 |
| Hypertension | 41 | 50.0 |
| Hypertension with diabetes | 7 | 8.5 |
| Prostatic Hypertrophy | 1 | 1.2 |
| Therapeutic characteristics at the time of presentation | ||
| Irbesartan/Lisinopril | 60 | 73.2 |
| NifecardXL | 43 | 52.4 |
| Gliclazide | 22 | 26.8 |
| CaCO3 | 21 | 25.6 |
| Fersolate | 20 | 24.4 |
| Lasix | 20 | 24.4 |
| Hydralazine | 18 | 22.0 |
| Folic acid | 15 | 18.3 |
| EPO | 12 | 14.6 |
| Methyldopa | 11 | 13.4 |
| Statin | 10 | 12.2 |
| NaHCO3 | 10 | 12.2 |
| Bisoprolol | 7 | 8.5 |
| Aspirin | 3 | 3.7 |
| Metformin | 3 | 3.7 |
| Ranitidine | 1 | 1.2 |
EPO: erythropoietin, CaCO3: calcium carbonate, NaHCO3: sodium bicarbonate